Detalhe da pesquisa
1.
Selective PP2A Enhancement through Biased Heterotrimer Stabilization.
Cell
; 181(3): 688-701.e16, 2020 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32315618
2.
Biased holoenzyme assembly of protein phosphatase 2A (PP2A): From cancer to small molecules.
J Biol Chem
; 298(12): 102656, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36328247
3.
Protein phosphatase 2A Aα regulates Aß protein expression and stability.
J Biol Chem
; 294(15): 5923-5934, 2019 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30796164
4.
Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45).
J Biol Chem
; 294(45): 17043-17059, 2019 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562245
5.
Effects of Two Group Prenatal Care Interventions on Mental Health: An RCT.
Am J Prev Med
; 66(5): 797-808, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38323949
6.
Integrated stress response plasticity governs normal cell adaptation to chronic stress via the PP2A-TFE3-ATF4 pathway.
Res Sq
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38585734
7.
PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis.
J Clin Invest
; 133(13)2023 07 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37166997
8.
Small-Molecule-Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death.
Mol Cancer Ther
; 22(5): 599-615, 2023 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36788429
9.
Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance.
Nat Commun
; 14(1): 5253, 2023 08 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37644036
10.
Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.
Cancer Res
; 82(4): 721-733, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34921012
11.
Splice of Life for Cancer: Missplicing of PPP2R5A by Mutant SF3B1 Leads to MYC Stabilization and Tumorigenesis.
Cancer Discov
; 10(6): 765-767, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32482664
12.
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
Oncogene
; 39(3): 703-717, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31541192
13.
The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies.
PLoS One
; 15(10): e0240169, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33027304
14.
The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.
Cancer Res
; 79(16): 4242-4257, 2019 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31142515
15.
Therapeutic targeting of PP2A.
Int J Biochem Cell Biol
; 96: 182-193, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29107183
16.
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Sci Transl Med
; 10(450)2018 07 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30021885
17.
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.
J Clin Invest
; 127(6): 2081-2090, 2017 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28504649